相似文献
1
New dogmas or old?
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
2
NSAIDs: the emperor's new dogma?
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
3
Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly.
Clin Geriatr Med. 2001 Aug;17(3):489-502, vi. doi: 10.1016/s0749-0690(05)70082-3.
4
Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
Ann Intern Med. 2000 Jan 18;132(2):134-43. doi: 10.7326/0003-4819-132-2-200001180-00008.
5
[Selective COX-2 non-steroidal anti-inflammatory agents and gastrointestinal toxicity].
Rev Esp Enferm Dig. 2001 Dec;93(12):819-20.
6
Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
JAMA. 2000 Apr 19;283(15):1961; author reply 1962.
7
Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
JAMA. 2000 Apr 19;283(15):1961-2.
8
COX-2 inhibitors. What is their place?
Aust Fam Physician. 2000 Sep;29(9):847-52.
9
NSAIDs: gastroprotection or selective COX-2 inhibitors?
Palliat Med. 2005 Mar;19(2):165; author reply 166-7. doi: 10.1191/0269216305pm991xx.
10
The coxibs, selective inhibitors of cyclooxygenase-2.
N Engl J Med. 2001 Aug 9;345(6):433-42. doi: 10.1056/NEJM200108093450607.
引用本文的文献
1
Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions.
World J Gastroenterol. 2005 Oct 7;11(37):5828-33. doi: 10.3748/wjg.v11.i37.5828.
本文引用的文献
1
2
GASTRIC MUCOSAL INJURY BY FATTY AND ACETYLSALICYLIC ACIDS.
Gastroenterology. 1964 Mar;46:245-53.
3
Ability of some antirheumatic drugs to uncouple oxidative phosphorylation.
Nature. 1962 Dec 29;196:1323-4. doi: 10.1038/1961323a0.
4
NSAIDs: the emperor's new dogma?
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
5
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Gut. 2003 Jun;52(6):820-6. doi: 10.1136/gut.52.6.820.
6
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.
Gut. 2003 Apr;52(4):600-8. doi: 10.1136/gut.52.4.600.
7
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Gastroenterology. 2003 Feb;124(2):288-92. doi: 10.1053/gast.2003.50054.
8
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
BMJ. 2002 Sep 21;325(7365):619. doi: 10.1136/bmj.325.7365.619.
9
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.
Gastroenterology. 2002 Jun;122(7):1913-23. doi: 10.1053/gast.2002.33647.
10
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
BMJ. 2002 Jun 1;324(7349):1287-8. doi: 10.1136/bmj.324.7349.1287.
Zotero 插件